GlassScriptPhysician profile
Evan D Cole
NPI 1710989900
$13,468.62
in general payments reported to CMS, 2019-2025
49 companies · $3,011 in 2025
The $3,011 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $723 · 2021: $1,585 · 2022: $1,636 · 2023: $2,681 · 2024: $2,979 · 2025: $3,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,670.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,782.09 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,431.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,158.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,149.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $1,059.28 | 2022-2025 | Azstarys, Azstarys |
| Lilly USA, LLC | $923.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $896.97 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $485.14 | 2022-2025 | |
| Axsome Therapeutics, INC. | $460.01 | 2023-2025 | Auvelity, Sunosi |
| Amgen INC. | $393.22 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $346.53 | 2023-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.60 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.24 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Astellas Pharma US INC | $294.87 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $280.30 | 2023-2025 | Cologuard Collection Kit |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.